
Opinion|Videos|June 19, 2024
Complement System Role in PNH Treatment Approach
Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does an understanding of the complement system’s role in paroxysmal nocturnal hemoglobinuria inform therapeutic approaches or interventions for patients with this condition?
Advertisement
Related to this article

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
4
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
5

